VCANBIO's subsidiary VUM03 injection has received the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.VCANBIO's wholly-owned subsidiary Wuhan Optics Valley VCANBIO Pharmaceutical received approval from the National Medical Products Administration on March 28 for VUM03 injection to treat inactive/mildly active Crohn's disease complex anal fistula. This injection is a cryopreserved cell preparation independently developed by the company, aimed at meeting clinical needs. By February 2025, the company's cumulative investment in the research and development of this project will reach 7.0933 million yuan
According to the Zhitong Finance APP, VCANBIO (600645.SH) announced that its wholly-owned subsidiary Wuhan Optics Valley VCANBIO Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on March 28 for the use of VUM03 injection in the treatment of non-active/mildly active Crohn's disease complex anal fistula.
VUM03 injection (human umbilical cord-derived mesenchymal/stromal cell injection) is a cryopreserved cell preparation independently developed by our company, made from selected healthy newborn umbilical cord tissue through in vitro separation, amplification, harvesting, and cryopreservation to prepare human umbilical cord-derived mesenchymal/stromal cells (UC-MSC) new drug. This product is developed as a general-purpose, ready-to-use cell preparation to meet clinical local usage needs, and is intended for the treatment of non-active/mildly active Crohn's disease complex anal fistula. As of February 2025, the company's cumulative R&D investment in this project amounts to RMB 7.0933 million